Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities
Y. Zhang, D. Remillard, U. Onubogu, B. Karakyriakou, J. N. Asiaban, A. R. Ramos, K. Bowland, T. R. Bishop, C. J. Ott, M. Janiszewska, B. F. Cravatt, M. A. Erb
The paper identifies collateral synthetic lethality between HDAC1 and HDAC2 in cancer cells and shows that targeting HDAC2 can suppress tumor growth by disrupting the NuRD complex.
bioRxiv · May 30, 2022Cancer Biology